Details for Patent: 6,008,207
✉ Email this page to a colleague
Summary for Patent: 6,008,207
Title: | Anhydrous alendronate monosodium salt formulations |
Abstract: | Disclosed is a method for treating and preventing bone loss in patients by administering a formulation of anhydrous alendronate sodium. Also described is a pharmaceutical doage form of said anhydrous alendronate sodium, being anhydrous 4-amino-1-hydroxy-butylidene-1,1-bisphosphonic acid, monosodium salt, in a pharmaceutically acceptable excipient. |
Inventor(s): | Brenner; Gerald S. (Norristown, PA), Ostovic; Drazen (Lansdale, PA), Oberholtzer, Jr.; Earl R. (Hatfield, PA), Thies; J. Eric (Scotch Plains, NJ) |
Assignee: | Merck & Co., Inc. (Rahway, NJ) |
Application Number: | 09/133,200 |
Patent Claim Types: see list of patent claims | Use; Composition; | More… ↓ |
Drugs Protected by US Patent 6,008,207
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |